Epidemiological and clinical studies consistently show that anxiety and depression are highly prevalent among individuals with functional neurological disorder (FND). Across outpatient neurology and specialized FND clinics, estimates suggest that at least half of patients meet criteria for a current anxiety or depressive disorder, and lifetime rates are even higher. Many cohorts report that between 50–70% of people with FND have clinically significant symptoms of depression, while 40–60% experience anxiety disorders such as generalized anxiety disorder, panic disorder, or post‑traumatic stress disorder. These figures often exceed those found in other neurological conditions, underscoring the central role of psychiatric comorbidity in FND rather than depicting it as a secondary or incidental issue.
The reported prevalence varies depending on the clinical setting, diagnostic criteria, and methods of assessment. Studies that use structured diagnostic interviews tend to find higher rates of both anxiety and depression than those relying on routine clinical impressions or brief questionnaires. Tertiary referral centers and inpatient units, which typically serve more complex and severe cases, frequently publish the highest prevalence estimates. In contrast, community samples or patients identified early in the course of symptoms sometimes show lower—but still substantial—levels of affective disturbance. Differences in sample characteristics, such as age distribution, gender balance, and duration of illness, further contribute to the variability in reported rates.
Comorbid anxiety and depression in FND often have an early onset, sometimes predating the development of functional symptoms by years. Longitudinal histories reveal that a sizable subset of patients report childhood or adolescent anxiety, persistent low mood, or recurrent depressive episodes before the emergence of motor or sensory symptoms. In other cases, affective symptoms arise in close temporal proximity to the onset of FND, potentially triggered by acute stress, physical illness, or interpersonal conflict. This temporal diversity suggests multiple developmental pathways, with anxiety and depression sometimes representing predisposing vulnerabilities and at other times acting as perpetuating or amplifying factors once FND has emerged.
High rates of comorbidity are not limited to classical major depressive disorder or generalized anxiety disorder. Subthreshold mood and anxiety symptoms, adjustment disorders, and trauma‑related conditions are also common. Even when diagnostic thresholds are not met, persistent worry, irritability, anhedonia, and sleep disturbance appear at levels that are clinically meaningful and linked to poorer functioning. As a result, strict categorical diagnoses likely underestimate the mental health burden experienced by many patients with FND. Dimensional approaches that quantify symptom severity rather than relying solely on yes/no diagnoses tend to reveal an even broader prevalence of clinically relevant emotional distress.
Sex and gender differences in the prevalence of anxiety and depression within FND broadly mirror patterns seen in the general population. Women with FND typically exhibit higher rates of affective disorders than men, although men are by no means spared. Some studies suggest that when FND presents in men, co‑occurring depression may be particularly under‑recognized, potentially due to gendered expectations around emotional expression, stigma, and differences in help‑seeking behavior. Age also influences prevalence, with younger adults more frequently endorsing high anxiety and older adults more likely to present with entrenched low mood, though findings are not entirely consistent across cohorts.
Medical and neurological comorbidities further shape the landscape of anxiety and depression in FND. Individuals with concurrent chronic pain, migraine, gastrointestinal disturbance, and fatigue syndromes exhibit especially high levels of affective symptoms. In these complex presentations, it can be challenging to disentangle the contributions of pain, sleep disruption, functional impairment, and illness uncertainty to overall mood and anxiety levels. Nonetheless, the clustering of these conditions underscores that FND often occurs in the context of a broader pattern of multisystem distress rather than as an isolated neurological phenomenon.
Underdiagnosis of psychiatric comorbidity remains a significant concern, even in specialized settings. Routine neurological evaluations frequently prioritize the characterization of motor or sensory manifestations, leaving anxiety and depression insufficiently explored. Without systematic screening, mild to moderate levels of emotional symptoms can be easily overlooked, particularly when patients minimize or normalize their psychological distress or when clinicians hesitate to “psychologize” symptoms they recognize as neurological in nature. This underestimation can lead to the erroneous impression that only a minority of patients with FND struggle with mood or anxiety disorders, contradicting the more robust findings from research using comprehensive assessments.
Stigma and explanatory models of illness also influence observed prevalence rates. Patients who strongly reject psychological explanations for their symptoms may be less willing to disclose anxiety, low mood, or trauma histories, which can artificially lower the recorded rates of comorbidity. Conversely, when clinicians offer a biopsychosocial understanding of FND that validates the genuineness of symptoms while acknowledging the role of stress and emotion, patients may feel safer reporting emotional difficulties. This dynamic highlights that prevalence estimates can be shaped not only by measurement tools but also by the therapeutic relationship and the language used to discuss functional symptoms.
Cross‑cultural research indicates that anxiety and depression are common across diverse geographic regions and health systems, although the specific prevalence figures and patterns differ. In some cultures, emotional distress is more likely to be expressed through physical complaints, which may contribute to the high rates of functional symptoms and complicate direct comparison with Western cohorts. Limited access to mental health services, differing levels of awareness about FND, and variations in diagnostic practices all affect the likelihood that anxiety or depression will be formally recognized alongside functional neurological symptoms. Nonetheless, the convergence of findings from multiple countries suggests that affective comorbidity is a core and ubiquitous feature of FND.
The available data portray a clinical population in which anxiety and depression are the rule rather than the exception. Recognizing the true prevalence of these conditions is essential, not only for accurate description of FND but also because they are closely linked to disability, health care utilization, and long‑term outcomes. The frequent co‑occurrence of mood and anxiety symptoms underscores the need for routine, structured screening and comprehensive evaluations in patients with FND, along with care models that attend to both neurological and psychological dimensions of the disorder.
Clinical characteristics and symptom profiles
Patients with functional neurological disorder present with a wide array of symptom patterns, and those with comorbid anxiety or depression often display particularly complex clinical pictures. Motor manifestations such as limb weakness, tremor, dystonia, gait disturbance, and episodes resembling seizures frequently coexist with prominent sensory changes, including numbness, visual blurring, non‑dermatomal pain, or hearing difficulties. In many individuals, these neurological symptoms fluctuate substantially over short periods, are influenced by attention and emotional state, and may show internal inconsistency on examination—for example, marked weakness during formal testing but preserved function in spontaneous movements. These hallmark features of FND can be amplified when anxiety heightens bodily vigilance or when low mood reduces tolerance for physical sensations, reinforcing cycles of symptom monitoring and avoidance.
Episodes that resemble epileptic seizures—often referred to as functional seizures or psychogenic nonepileptic seizures (PNES)—constitute a prominent symptom profile in which anxiety and depression are especially common. Patients may report prodromal sensations of rising panic, derealization, or emotional overwhelm before an event, or conversely describe a “blank” or emotionally numbed state preceding loss of responsiveness. Following seizures, many describe exhaustion, shame, and hopelessness, which can deepen existing depressive symptoms. The unpredictability of spells fosters anticipatory anxiety about when and where the next episode will occur, frequently leading to activity restriction, social withdrawal, and dependence on caregivers, thereby entrenching disability.
Functional movement disorders exhibit their own pattern of interaction with comorbid affective symptoms. Tremor and jerks may become more prominent during anxious anticipation, medical appointments, or performance situations, reflecting heightened arousal and selective attention to the affected body part. Conversely, symptoms may diminish when patients are distracted, engrossed in conversation, or performing automatic tasks. Individuals with painful dystonia or fixed postures often report chronic low mood, irritability, and sleep disturbance related both to ongoing discomfort and to the loss of previously valued physical activities. Over time, the combination of persistent pain, altered body image, and social misunderstandings about the legitimacy of symptoms can contribute to a more pervasive depressive state.
In sensory and cognitive presentations of FND, clinical characteristics frequently blend with anxiety‑driven misinterpretations of bodily signals. Patients may describe intermittent blindness, tunnel vision, or double vision that appears in specific contexts, such as bright lights, crowded spaces, or periods of emotional stress. Similarly, functional cognitive symptoms—often described as “brain fog,” difficulty concentrating, or feeling mentally slowed—are tightly interwoven with worry about early‑onset dementia or irreversible brain damage. The resulting preoccupation with cognitive performance can ironically worsen subjective impairment, as anxious rumination consumes attentional resources and encourages repetitive self‑testing. These symptom profiles can be mistaken for primary neurodegenerative or ophthalmologic conditions unless the context and internal inconsistencies are carefully explored.
Across FND subtypes, autonomic and somatic complaints are commonplace and often overlap with classic anxiety symptoms. Palpitations, shortness of breath, dizziness, gastrointestinal upset, and urinary frequency may be experienced both as triggers and consequences of functional attacks. Patients frequently report that they first noticed bodily sensations compatible with panic—rapid heart rate, chest tightness, trembling—long before formal FND was diagnosed, and that they interpreted these as signs of medical catastrophe rather than anxiety. Over time, this pattern can lead to hypervigilance to interoceptive cues and repeated emergency presentations, with each negative test paradoxically failing to reassure and instead reinforcing the sense that something elusive and serious is being missed.
Sleep disturbance represents a cross‑cutting feature in many clinical profiles. Difficulties with falling asleep, nocturnal awakenings, nightmares, and nonrestorative sleep are widely reported, particularly in those with high levels of anxiety, post‑traumatic stress, or low mood. Poor sleep, in turn, worsens daytime fatigue, cognitive inefficiency, pain sensitivity, and emotional reactivity, creating a self‑perpetuating loop. Morning exacerbations of weakness, tremor, or functional gait problems are often temporally linked to sleep disruption and overnight rumination, rather than to structural neurological deterioration. Recognizing these bidirectional links allows clinicians to target sleep as a modifiable contributor to symptom intensity and daily functioning.
Psychological and interpersonal characteristics further shape symptom profiles. Many individuals with FND and comorbid depression describe a longstanding pattern of self‑criticism, perfectionism, or a strong need to meet perceived expectations of others. When illness interrupts work, caregiving, or academic performance, these traits can produce profound feelings of failure and guilt, amplifying depressive cognition. Patients may oscillate between overexertion on “good” days—attempting to prove to themselves and others that they are not malingering—and subsequent worsening of fatigue and functional symptoms, which confirms fears of permanent damage or weakness. This boom‑and‑bust cycle is especially pronounced in those with comorbid chronic pain or fatigue syndromes.
Trauma histories are common in many, though not all, patients with FND and are closely related to particular symptom constellations. Individuals with prior physical or sexual abuse, combat exposure, or severe medical trauma may experience dissociative episodes, emotional numbing, or flashbacks in conjunction with their functional neurological symptoms. Functional seizures, for example, may contain elements of re‑enactment, with postures or sensations reminiscent of past traumatic experiences, even when the individual is not consciously aware of the connection. Chronic hyperarousal associated with post‑traumatic stress can lower the threshold for functional symptoms to emerge, while avoidance of trauma reminders can limit engagement in treatment and daily activities. The presence of trauma often coexists with substantial anxiety and depression, resulting in layered clinical presentations that require careful, nonjudgmental exploration.
Emotional processing styles also influence how symptoms are expressed. Some patients display high levels of overt worry, frequent health‑related checking, and repeated verbalization of fears about their prognosis. Others exhibit alexithymia or limited awareness of internal emotional states, reporting physical complaints in detail but describing their feelings as “fine” or “normal” despite clear behavioral signs of distress. In the latter group, affective arousal may be channeled preferentially into bodily symptoms, with functional weakness, sensory loss, or seizures serving as the primary mode of expressing and regulating internal tension. These differing profiles have implications for how patients respond to psychoeducation and psychotherapy, as interventions may need to emphasize emotion identification and labeling in some, and cognitive restructuring of catastrophic thoughts in others.
Interpersonal patterns around illness and care seeking contribute another layer of clinical nuance. Some patients with marked anxiety make frequent visits to emergency departments or request repeated diagnostic testing, driven by fear that a serious organic disease has been overlooked. Others, particularly those with entrenched depression, may disengage from follow‑up appointments, express resignation about the possibility of improvement, or be perceived as “difficult” or “noncompliant.” Family responses range from highly protective and accommodating—taking over most activities of daily living—to skeptical or invalidating, questioning whether symptoms are “real.” These dynamics can either support or undermine self‑efficacy and adherence to treatment plans. Recognizing patterns of reassurance seeking, over‑protection, or conflict helps explain why similar neurological presentations may lead to very different functional outcomes.
Clinically, patterns of symptom onset and course show substantial heterogeneity, but certain trajectories are more common in individuals with pronounced anxiety and depression. Some experience an abrupt onset following a discrete stressor, minor injury, or medical event, with rapid escalation of symptoms and health care use. Others show a more insidious course, with years of fluctuating pain, fatigue, or autonomic symptoms gradually giving way to more overt functional motor or seizure‑like events. In both patterns, affective symptoms may wax and wane with changes in life stress, social support, and perceived control over symptoms. Periods of improvement often coincide with better mood, structured routines, and clear treatment plans, while relapses are associated with renewed uncertainty, interpersonal conflict, or loss.
There is also wide variability in insight and explanatory models among patients. Some explicitly link their functional symptoms to stress, trauma, or worry, and can describe how episodes worsen during periods of high emotional strain. Others firmly attribute symptoms to structural brain disease, infection, or toxins, and reject any role for mood or anxiety, sometimes due to prior experiences of being dismissed. This diversity in illness narratives is itself a clinical characteristic, as it shapes engagement with both neurological and psychological services. Patients who can integrate a biopsychosocial understanding of FND tend to describe more flexible coping strategies and are often more open to interventions targeting anxiety, depression, and functional symptoms together.
The patterning of comorbidity across different symptom clusters is clinically informative. For instance, those with predominantly functional seizures show particularly high rates of trauma‑related disorders and panic symptoms, whereas individuals with functional movement disorders may more often report chronic pain, fatigue, and depressive features like anhedonia and hopelessness. Patients whose presentations center on cognitive complaints frequently endorse generalized anxiety, health anxiety, and insomnia. These associations are not absolute but can guide targeted questions during assessment and help anticipate potential barriers to treatment. Paying attention to the configuration of neurological and affective symptoms, rather than treating them as separate silos, provides a richer and more accurate understanding of each person’s clinical profile.
Impact of comorbidity on functional outcomes
The presence of anxiety and depression in individuals with functional neurological disorder exerts a powerful influence on day‑to‑day functioning, often more so than the apparent severity of the neurological symptoms themselves. Comorbidity is consistently associated with greater disability in basic and instrumental activities of daily living, including walking, self‑care, household tasks, parenting, and employment. Patients with pronounced low mood or high anxiety frequently report that they are unable to leave the house alone, travel on public transportation, or tolerate crowded environments for fear of symptom exacerbation or public embarrassment during functional seizures or visible movement abnormalities. Over time, this restriction of activity leads to deconditioning, loss of confidence, and shrinking social networks, each of which further undermines functional independence.
Occupational functioning is particularly vulnerable when comorbid anxiety and depression are present. Many people with FND struggle to maintain employment, not only because of episodic weakness, tremor, or seizures, but also due to cognitive symptoms, fatigue, and reduced stress tolerance linked to affective disturbance. Those with high anxiety may avoid work settings that feel unpredictable or demanding, while individuals with depression often describe diminished motivation, slower processing speed, and difficulty initiating tasks. Even when employers are willing to offer accommodations, frequent absences, reduced productivity, and concerns about safety in certain roles (for example, operating machinery, driving, or working at heights) can result in job loss or long‑term sick leave. Studies repeatedly show that worse mood symptoms predict unemployment and reduced likelihood of returning to work, even when neurological symptom severity is statistically controlled.
Social participation and role functioning outside the workplace are also shaped by this comorbidity. Fear of having a seizure, falling, or losing control in public spaces drives many patients to withdraw from hobbies, religious activities, and social gatherings. In families, partners and children may assume additional caregiving responsibilities, which can strain relationships and alter family roles. Individuals with depression frequently describe feeling like a burden, which can lead to self‑imposed isolation, reduced communication, and less willingness to seek help when symptoms worsen. These interpersonal shifts contribute to poorer outcomes over time, as social support is a critical buffer against both FND symptoms and affective distress.
Health‑related quality of life is markedly reduced in FND, and severity of anxiety and depression is one of the strongest predictors of this reduction. High levels of worry, rumination, and hopelessness color patients’ perceptions of their health, amplify pain and fatigue, and diminish enjoyment of previously meaningful activities. Even on days when functional symptoms are milder, persistent low mood can prevent individuals from recognizing or capitalizing on small improvements, reinforcing a sense of stagnation or inevitable decline. Quality‑of‑life measures frequently reveal impairments on par with or exceeding those seen in many chronic neurological and medical conditions, and these impairments are most pronounced in those with multiple psychiatric comorbidities.
The pattern of health care utilization provides another window into the impact of comorbidity on functional outcomes. Patients with prominent anxiety and depression often present repeatedly to emergency departments and urgent care settings, particularly when experiencing functional seizures, chest pain, or sudden weakness. Recurrent negative investigations and inconclusive findings can paradoxically heighten health anxiety and mistrust, leading to further consultations and requests for additional testing. Those with entrenched depression may oscillate between high utilization during crisis periods and disengagement from outpatient follow‑up when hope for improvement wanes. This irregular pattern contributes to fragmented care, delayed implementation of evidence‑based interventions, and escalating costs without corresponding gains in functioning.
Long‑term prognosis in FND is closely tied to the trajectory of comorbid mood and anxiety disorders. Follow‑up studies indicate that individuals whose depressive and anxiety symptoms remain high over time are more likely to experience chronic, fluctuating neurological symptoms, sustained disability, and limited occupational recovery. In contrast, patients who achieve partial or full remission of affective symptoms are more likely to show functional gains, even if some neurological manifestations persist. Improvement in mood often correlates with increased activity levels, better adherence to physiotherapy and psychological treatment, and a more flexible approach to symptom management. These associations underscore that addressing comorbid psychopathology is not simply an adjunct to treating FND but a central determinant of outcomes.
Fear‑avoidance mechanisms provide one explanatory pathway for how comorbidity drives functional impairment. When bodily sensations or movements are interpreted through a lens of anxiety—such as perceiving palpitations as signs of imminent cardiac arrest or transient weakness as evidence of a progressive neurological disease—patients are more likely to avoid activities that might provoke those sensations. This avoidance reduces opportunities for corrective learning (for example, discovering that walking short distances does not actually trigger collapse), thereby maintaining both the fear and the functional limitation. Depression contributes by eroding the motivation and energy needed to engage in graded exposure or rehabilitation exercises, making it harder to break these cycles even when patients intellectually understand the rationale for behavioral change.
Self‑efficacy and beliefs about control over symptoms represent another pathway linking comorbidity to functional outcomes. Individuals with high anxiety or depression commonly endorse beliefs that their symptoms are unpredictable, uncontrollable, and inevitably worsening. These cognitions reduce perceived agency and foster passive coping strategies, such as excessive rest, over‑reliance on medications, or waiting for a definitive biomedical “cure” before resuming activity. Such strategies may provide temporary relief but often consolidate disability by weakening muscles, disrupting sleep‑wake cycles, and reinforcing the perception of being severely ill. Interventions that directly target these beliefs—helping patients recognize patterns of fluctuation, identifying activities that are safe despite symptoms, and practicing skills to modulate arousal—are associated with better functional gains, emphasizing the mediating role of mood and cognition.
Comorbid trauma‑related disorders, including post‑traumatic stress, add additional complexity to functional outcomes. Hyperarousal, intrusive memories, and avoidance of trauma reminders can intersect with FND symptoms in ways that limit participation in everyday environments. For instance, a patient whose functional seizures are triggered by loud noises or crowded spaces may avoid public transportation, shopping centers, or workplaces that resemble the context of prior trauma. This narrowing of the “safe” world restricts opportunities for social and occupational engagement and can impede exposure‑based or physiotherapy‑focused treatments if the therapy setting itself is experienced as threatening. Moreover, the chronic threat perception inherent in trauma‑related anxiety can keep the nervous system in a heightened state of arousal, lowering the threshold for functional symptoms and perpetuating disability.
Family and caregiver responses modulate how comorbidity translates into functional consequences. In households where anxiety about the patient’s safety is high, relatives may inadvertently encourage dependence by taking over tasks that the patient could perform with support and pacing. While well intentioned, these accommodations can reduce opportunities for graded exposure to feared activities and reinforce beliefs of fragility. Conversely, family members who respond to depression with criticism, disbelief, or pressure to “snap out of it” may exacerbate hopelessness and shame, making it harder for the patient to attempt functional goals or seek mental health treatment. Interventions that educate families about FND, explain the role of anxiety and mood in symptom maintenance, and promote supportive but autonomy‑enhancing behaviors are associated with improved participation and reduced conflict.
Engagement with rehabilitation and psychological interventions is itself influenced by comorbid anxiety and depression, which in turn affects outcomes. Patients who are highly anxious about movement or symptom exacerbation may be reluctant to participate fully in physiotherapy, fearing that exercise will cause harm or precipitate a severe episode. Those with significant depression may struggle to attend regular appointments, complete home exercises, or sustain the effort required for cognitive‑behavioral or trauma‑focused therapies. Clinicians often observe that improvements in affective symptoms—through psychotherapy, pharmacotherapy, or combined approaches—lead to better adherence and greater openness to testing new behaviors. Thus, early identification and treatment of mood and anxiety symptoms can improve the effectiveness of FND‑specific rehabilitation by increasing readiness for change and resilience in the face of temporary setbacks.
Suicidal ideation and self‑harm behaviors, more common in individuals with FND who have severe depression or co‑occurring personality difficulties, represent a particularly serious impact of comorbidity on functional and life outcomes. Frequent crises related to suicidality can disrupt rehabilitation programs, necessitate psychiatric hospitalization, and consume emotional and practical resources that might otherwise be directed toward long‑term functional goals. Furthermore, persistent thoughts of death or self‑harm reflect a profound erosion of hope and life satisfaction, which undermines the motivational basis for engaging in challenging rehabilitative work. Systematic screening for suicidality and provision of appropriate crisis and safety planning are therefore essential components of managing FND populations with high psychiatric burden.
From a systems perspective, clinics that adopt integrated care models—bringing together neurology, psychiatry, psychology, physiotherapy, and social work—tend to report better functional outcomes than services that address these elements separately or sequentially. When mood and anxiety symptoms are assessed and treated in parallel with neurological rehabilitation, patients receive consistent messaging about the interconnectedness of emotional and physical symptoms, reducing confusion and stigma. This alignment allows for coordinated goal setting, in which improvements in walking, self‑care, or seizure frequency are pursued alongside reduction in depressive and anxiety symptoms. By contrast, fragmented care, in which each clinician focuses narrowly on their own domain, often leaves patients feeling bounced between services, uncertain about priorities, and less likely to achieve sustained functional gains.
Socioeconomic consequences also reflect the impact of comorbidity on functioning. Individuals with FND and persistent anxiety or depression are more likely to rely on disability benefits, experience financial strain, and face challenges in securing housing or transportation. These stressors feed back into the clinical picture by increasing worry, limiting access to treatment (for example, inability to pay for transportation to appointments), and constraining opportunities for activities that could enhance self‑esteem and social connection. Addressing practical barriers—through vocational rehabilitation, social work support, and advocacy around workplace accommodations—can therefore indirectly improve both psychological well‑being and functional status.
Not all effects of comorbidity are uniformly negative; variability in resilience, coping strategies, and access to support means that some individuals maintain relatively good functioning despite significant anxiety or low mood. Factors such as strong social networks, adaptive problem‑solving skills, and prior positive experiences with mental health care can buffer the impact of comorbidity. Nonetheless, when examining groups of patients with FND, the consistent pattern is that higher levels of depression and anxiety are associated with more severe disability, poorer quality of life, and less favorable long‑term trajectories. Recognizing this pattern encourages clinicians and health systems to treat psychiatric comorbidity as a central, modifiable target rather than as a peripheral or secondary concern.
Assessment and diagnostic considerations
Assessment of anxiety, depression, and other psychiatric conditions in the context of functional neurological disorder requires deliberate planning rather than ad hoc questioning. Routine, structured screening is essential, because comorbidity is frequently under‑recognized when evaluations focus solely on neurological signs. Incorporating standardized self‑report instruments—such as the Patient Health Questionnaire‑9 for depressive symptoms, the Generalized Anxiety Disorder‑7 scale for anxiety, and brief PTSD or trauma checklists—provides an efficient first pass at identifying clinically significant distress. These tools are not diagnostic on their own, but they highlight individuals who need more in‑depth assessment and can be repeated over time to monitor change.
A thorough clinical interview remains the cornerstone of assessment. In addition to eliciting a detailed history of functional symptoms, clinicians should ask systematically about past and current mood, worry, panic attacks, trauma exposure, substance use, and prior psychiatric treatment. Attention to chronology is critical: clarifying whether anxiety or depression predated the onset of FND, emerged concurrently, or developed secondarily to disability and stigma helps inform case formulation and treatment priorities. The interview should explore typical daily routines, sleep patterns, energy levels, and anhedonia, as these often reveal more about the severity of affective disturbance than answers to direct questions about “feeling depressed.”
Diagnostic differentiation between functional neurological symptoms and primary psychiatric disorders with somatic manifestations is an important consideration. Conditions such as panic disorder, somatic symptom disorder, conversion disorder (functional neurological symptom disorder), and dissociative disorders can overlap substantially in presentation. Clinicians must identify positive neurological signs of FND—such as inconsistency, incongruity with recognized neuroanatomical patterns, and symptom modulation with distraction—rather than assigning a diagnosis by exclusion. At the same time, they need to evaluate whether the level of preoccupation with symptoms, health anxiety, or catastrophic interpretation of bodily sensations warrants additional diagnoses like illness anxiety disorder or somatic symptom disorder.
Cognitive and dissociative phenomena warrant explicit assessment. Many patients describe episodes of depersonalization or derealization, gaps in memory, or feeling as though they are observing events from outside their body, particularly around functional seizures or intense affective states. Structured instruments such as dissociation scales can help quantify these experiences, but careful open‑ended questioning is often sufficient to detect clinically relevant dissociation. Because dissociative symptoms are associated with trauma histories and with poorer treatment outcomes, their presence should prompt more detailed exploration of past adversity and current triggers, as well as consideration of trauma‑focused interventions.
Assessment of risk is a non‑negotiable component when depression or severe emotional distress is suspected. Clinicians should ask directly about suicidal ideation, past suicide attempts, self‑harm behaviors, and thoughts of harming others. Shame and fear of hospitalization may lead some individuals to minimize risk unless they are asked in a calm, nonjudgmental manner. Determining the frequency, intensity, and specificity of suicidal thoughts, as well as access to means and protective factors, informs decisions about the level of care required and the urgency of psychiatric referral. Safety planning, involving both the patient and, when appropriate, family members, should be integrated into the broader management of FND in high‑risk cases.
Neuropsychological assessment can be valuable in selected patients, particularly those whose main complaints involve cognitive symptoms such as memory lapses, concentration problems, or “brain fog.” Formal testing helps distinguish between functional cognitive difficulties, cognitive effects of severe anxiety or depression, and genuine neurodegenerative or structural brain disease. Patterns such as variable performance across similar tasks, better functioning in unstructured conversation than on tests, and disproportionate subjective complaints relative to objective impairment are more consistent with functional or affective mechanisms. Feedback from neuropsychological evaluation can be used therapeutically to normalize findings, reduce catastrophic interpretations, and guide compensatory strategies.
Because many individuals with FND have complex medical histories and overlapping physical symptoms, assessment should extend beyond the individual to include collateral information and prior records when possible. Input from family members, partners, or caregivers can clarify the frequency and typical triggers of functional seizures, gait problems, or apparent episodes of unresponsiveness. They may also provide insight into mood changes, avoidance behaviors, and functional capacity at home that differ from what is reported in the clinic. Reviewing past imaging, EEGs, and laboratory results can prevent unnecessary duplication of tests, reduce iatrogenic reinforcement of illness concerns, and highlight the point at which further biomedical investigation is unlikely to change management.
Cultural, linguistic, and health literacy factors shape how symptoms are expressed and how questions about anxiety, depression, or trauma are understood. Clinicians should avoid assuming that the absence of psychological language indicates the absence of psychological distress; in some cultures, emotional pain is primarily communicated through somatic complaints, spiritual idioms, or interpersonal metaphors. Using interpreters who are familiar with mental health terminology, checking understanding of diagnostic terms, and asking about culturally specific explanations for symptoms can prevent misinterpretation and build trust. Adapting screening tools to the individual’s language and literacy level, or using orally administered versions when reading is difficult, increases the accuracy of assessment.
Physical examination and neurological testing should be conducted in ways that align with, rather than undermine, psychological assessment. Demonstrating positive signs of FND—for example, improvement of weakness with distraction or inconsistency between seated and supine strength—provides a basis for explaining the diagnosis in terms that integrate brain function, attention, and emotion. When these findings are clearly communicated, patients are often more receptive to later discussions about the role of stress, mood, and cognitive patterns in symptom maintenance. Conversely, ambiguous explanations or an exclusive focus on ruling out structural disease can fuel ongoing health anxiety and skepticism about psychological interventions.
Assessment is also the stage at which clinicians can begin shaping more adaptive illness narratives. Providing a coherent, non‑stigmatizing explanation that FND is a disorder of brain functioning rather than of brain damage helps validate the genuineness of symptoms while opening the door to behavioral and psychological treatment. Linking anxiety, depression, or trauma to symptom fluctuations in concrete terms—such as noting that functional seizures tend to occur after interpersonal conflict or during periods of sleep deprivation—can help patients recognize patterns they had not previously connected. This collaborative formulation lays the groundwork for shared decision‑making about treatment priorities and fosters a sense of partnership rather than adversarial interaction.
The question of who should conduct psychiatric assessment in FND depends on local resources, but collaboration between neurology and mental health professionals is widely regarded as best practice. In integrated care models, joint clinics or case conferences allow neurologists, psychiatrists, psychologists, physiotherapists, and nurses to share observations and align their formulations. This reduces conflicting messages to the patient about whether symptoms are “neurological” or “psychological” and enables coordinated plans that address both affective comorbidity and functional impairment. Even in settings without formal joint services, establishing clear referral pathways and channels for feedback between specialties improves continuity and treatment outcomes.
Standardized documentation of comorbidity is important for both clinical and research purposes. Recording specific DSM or ICD diagnoses, as well as dimensional ratings of symptom severity, allows clinicians to track the course of anxiety, depression, and trauma‑related symptoms alongside changes in functional neurological manifestations. This information can guide treatment sequencing—for example, deciding whether to prioritize stabilization of severe PTSD before intensive physiotherapy—and can help identify subgroups of patients who may benefit from tailored interventions. From a research perspective, careful characterization of psychiatric profiles improves the comparability of studies and enhances understanding of prognostic factors.
Assessment should explicitly address patient goals, values, and expectations. Asking what improvements would be most meaningful—such as returning to work part time, driving locally, caring for children independently, or reducing the frequency of emergency visits—clarifies how mood and anxiety interact with functional aspirations. Some individuals may initially prioritize exhaustive diagnostic testing over psychological treatment; exploring the beliefs underlying this preference (for example, fear of being disbelieved, prior experiences of misdiagnosis, or cultural views of mental illness) can inform how information is presented and what supports are needed to shift toward a more rehabilitative focus. By aligning assessment with the patient’s own framework and aspirations, clinicians create a more solid foundation for collaborative care that addresses both FND and its psychiatric comorbidities.
Implications for treatment and prognosis
Treatment planning is most effective when it explicitly acknowledges the bidirectional relationship between functional neurological symptoms and comorbid anxiety and depression. Explaining to patients that interventions will target both sets of problems in tandem—rather than treating mood or neurological manifestations as secondary—helps legitimize psychological care and reduces fears that physical symptoms are being dismissed. Early psychoeducation is central: describing FND as a disorder of brain functioning, in which networks involved in attention, movement, sensation, and emotion become dysregulated, provides a coherent rationale for why psychological and rehabilitative strategies can produce tangible physical changes. Clarifying that improvement is often gradual and non‑linear sets realistic expectations and helps patients interpret temporary setbacks as part of the process rather than evidence of treatment failure.
Multidisciplinary and integrated care models are strongly favored for managing FND with psychiatric comorbidity. Coordinated input from neurology, psychiatry, psychology, physiotherapy, occupational therapy, and social work allows treatment to address the full spectrum of symptoms and functional limitations. Joint case discussions and, where feasible, combined clinics ensure that all team members use consistent language when explaining the diagnosis and goals of therapy. This cohesion reduces confusion that can arise when one clinician emphasizes structural exclusion and another focuses on psychological mechanisms, and it supports unified messaging that both the neurological and emotional aspects of the condition are real, important, and modifiable. Such integrated pathways have been associated with improved adherence, reduced health care utilization, and better long‑term outcomes.
Psychological therapies occupy a central role in treatment, particularly for addressing anxiety, depression, and related cognitive and behavioral patterns that maintain functional symptoms. Cognitive‑behavioral approaches typically focus on identifying catastrophic interpretations of bodily sensations, challenging beliefs about damage or uncontrollability, and gradually increasing engagement in avoided activities. For patients with prominent panic or health anxiety, interoceptive exposure and behavioral experiments can demonstrate that feared sensations—such as palpitations, dizziness, or transient weakness—are uncomfortable but not dangerous, thereby weakening fear‑avoidance cycles. When low mood and anhedonia are prominent, behavioral activation techniques help patients reintroduce valued activities in a graded fashion, counteracting withdrawal and passivity that reinforce disability.
For individuals whose FND occurs in the context of trauma histories or post‑traumatic stress, trauma‑focused therapies may be indicated alongside or following initial stabilization. Approaches such as prolonged exposure, cognitive processing therapy, or eye movement desensitization and reprocessing aim to reduce the intensity and intrusiveness of trauma memories and to shift maladaptive beliefs about safety, guilt, and control. These interventions require careful pacing and close coordination with the broader team to avoid exacerbating functional symptoms or overwhelming coping resources. In some cases, therapists initially prioritize skills for grounding, emotion regulation, and dissociation management before engaging in direct trauma processing, particularly for patients who experience frequent functional seizures or severe dissociative episodes during emotional arousal.
Specialized psychotherapies designed or adapted specifically for FND integrate principles from cognitive‑behavioral, psychodynamic, and acceptance‑based models. These interventions often emphasize the role of attention and expectation in symptom generation, helping patients practice shifting focus away from affected body parts and toward goal‑directed actions. Techniques from acceptance and commitment therapy, such as identifying personal values and committing to small, values‑consistent behaviors despite symptoms, can be particularly useful when depression has narrowed life activities. For some patients, psychodynamic or interpersonal approaches that explore longstanding patterns of emotional expression, relationship dynamics, and self‑criticism are helpful in addressing deeper vulnerabilities that contribute to both mood disturbance and the persistence of functional symptoms.
Physiotherapy and occupational therapy are key components of treatment, especially for motor and gait manifestations, and their effectiveness is enhanced when therapists are attuned to comorbid anxiety and depression. Rather than focusing solely on strengthening or compensatory strategies, contemporary FND‑informed physiotherapy emphasizes retraining normal movement patterns through techniques that reduce self‑focused attention and build confidence. Graded exposure to feared or avoided movements, combined with clear explanations that movement is safe despite symptoms, helps weaken catastrophic beliefs and avoidance behaviors. Therapists can incorporate simple cognitive‑behavioral strategies—such as setting specific, achievable goals, praising effort over performance, and addressing negative predictions about failure—to counteract pessimism linked to low mood.
Pharmacological treatment may be indicated to manage moderate to severe depression, generalized anxiety, panic disorder, or trauma‑related symptoms that interfere with rehabilitation or quality of life. Selective serotonin reuptake inhibitors and serotonin‑norepinephrine reuptake inhibitors are commonly used first‑line agents, given their efficacy across multiple anxiety and mood disorders and generally favorable tolerability profiles. When prescribing psychotropic medications in FND, clinicians should explain that the goal is to treat co‑occurring psychiatric conditions and overall distress, not to directly “cure” functional symptoms. Framing medication as a tool that can improve sleep, energy, and emotional regulation—thereby making it easier to participate in physiotherapy and psychotherapy—can enhance acceptance and adherence. Regular monitoring is important to distinguish side effects from pre‑existing somatic symptoms and to adjust dosing based on clinical response.
Attention to sleep and circadian regulation is an often underappreciated therapeutic target with implications for both symptom severity and prognosis. Addressing insomnia, irregular sleep schedules, or excessive daytime napping through behavioral sleep interventions can yield improvements in fatigue, cognitive functioning, and emotional resilience. Psychoeducation about the relationship between nocturnal rumination, heightened physiological arousal, and functional symptom exacerbation helps patients understand why sleep hygiene recommendations—such as consistent bedtimes, limiting time in bed when not sleeping, and reducing late‑night screen use—are more than generic wellness advice. In some cases, short‑term pharmacological support for sleep may be warranted, but nonpharmacological strategies are preferred to avoid sedation, falls, or dependence, particularly in individuals with gait disturbance or frequent seizures.
Family and caregiver involvement has important implications for both treatment implementation and long‑term prognosis. Structured family sessions can provide education about FND, clarify how anxiety and depression interact with functional symptoms, and identify patterns of over‑protection, conflict, or skepticism that inadvertently maintain disability. Helping relatives shift from doing tasks for the patient to supporting them in doing tasks themselves, using graded goals and positive reinforcement, promotes autonomy and challenges beliefs about fragility. At the same time, families may need guidance on how to respond to acute episodes—such as functional seizures—in ways that ensure safety while minimizing excessive medicalization or reinforcement of avoidance. Addressing caregiver burden and emotional responses, including frustration, fear, or grief, can improve the relational environment in which recovery occurs.
Vocational rehabilitation and social support interventions play a crucial role in translating clinical gains into real‑world functional improvements. For many patients, structured support in exploring graded return‑to‑work options, negotiating accommodations, or considering alternative roles is necessary to overcome anxiety about performance and relapse. Collaboration between health providers, employers, and occupational health services can clarify realistic expectations and reduce the risk of abrupt transitions that overwhelm coping capacity. Social workers or case managers can help address financial stressors, transportation barriers, and housing instability that perpetuate low mood and constrain access to treatment. By aligning symptom management with concrete functional goals—such as driving short distances, caring for children independently, or reengaging in education—rehabilitation efforts become more meaningful and motivating.
Prognosis in FND with comorbid anxiety and depression is heterogeneous, shaped by a constellation of clinical, psychological, and contextual factors. Consistently, better outcomes are associated with early and clear communication of the diagnosis, timely access to appropriate multidisciplinary treatment, and active engagement in psychological and rehabilitative interventions. Patients who can adopt a biopsychosocial understanding of their condition, recognize links between mood, stress, and symptom fluctuations, and practice new coping strategies tend to show more substantial and sustained improvements. Conversely, delayed diagnosis, repeated unnecessary investigations, and communication that emphasizes diagnostic uncertainty or irreversibility are associated with entrenched disability and persistent distress.
The severity and chronicity of comorbid psychiatric conditions exert a particularly strong influence on long‑term trajectories. Individuals with longstanding, treatment‑resistant depression, complex trauma, or significant personality pathology often require prolonged, phased treatment, and their recovery in terms of functional outcomes may be slower and more variable. Nevertheless, even in these groups, targeted interventions can reduce crisis presentations, improve emotional stability, and support incremental gains in daily functioning. Recognizing that “full remission” of all symptoms may be unrealistic for some patients, clinicians can work collaboratively to define meaningful partial recovery—such as reduced seizure frequency, increased independence in self‑care, or improved participation in valued relationships—as legitimate and worthwhile goals.
Beliefs about prognosis held by both clinicians and patients have a powerful self‑fulfilling potential. When health professionals communicate pessimism, attribute symptoms primarily to intractable psychological pathology, or imply that little can be done, patients may internalize hopelessness and disengage from treatment. In contrast, messages that are realistic yet hopeful—emphasizing that while FND can be challenging and relapses may occur, many people experience significant improvement with appropriate care—can foster motivation and persistence. Sharing anonymized examples of recovery trajectories, where individuals moved from high disability to greater functioning over months or years, can help counteract catastrophic expectations forged by past negative experiences in health care systems.
Monitoring progress over time with repeated assessment of both functional status and psychiatric symptoms is essential for optimizing treatment and refining prognostic judgments. Regular use of brief mood and anxiety scales, alongside measures of mobility, self‑care, occupational functioning, and health‑related quality of life, allows clinicians to detect early signs of relapse or treatment plateau. These data can guide adjustments in therapy intensity, prompt reconsideration of unaddressed factors such as substance use or untreated sleep apnea, and support shared decision‑making about when to step down or intensify care. For some patients, periodic booster sessions after completion of a structured treatment program help consolidate gains, reinforce coping strategies, and address new stressors before they precipitate major setbacks.
Relapse and fluctuation are common features of FND and its comorbid conditions, and anticipating these patterns is critical for realistic treatment planning. Teaching patients to recognize early warning signs—such as increased rumination, withdrawal from activities, or subtle changes in gait or dissociation—enables them to implement self‑management strategies proactively. Collaborative development of written relapse prevention plans, including specific behavioral steps, coping skills, and points of contact within the care team, helps maintain a sense of control and reduces the likelihood that temporary worsening will escalate into prolonged crises. Framing relapses as opportunities to refine coping strategies rather than as evidence of failure supports psychological resilience and long‑term engagement.
Digital and remote interventions are emerging as important adjuncts or alternatives to traditional in‑person care, with potential benefits for accessibility and continuity, especially in regions where specialized FND services are scarce. Internet‑delivered CBT modules targeting health anxiety, panic, or depression, tele‑physiotherapy sessions focused on graded movement retraining, and app‑based tools for tracking symptoms and practicing grounding techniques can all extend the reach of evidence‑based strategies. While more research is needed to establish their comparative effectiveness, these modalities may improve outcomes by mitigating barriers such as travel fatigue, limited local expertise, or stigma associated with attending mental health services. Ensuring that digital tools incorporate clear education about FND and guidance on integrating skills into everyday activities is essential for maximizing their utility.
Across these diverse treatment avenues, an overarching principle is the integration of care for comorbid anxiety and depression with interventions targeting functional symptoms. Rather than viewing psychiatric and neurological elements as separate problems to be addressed sequentially, effective management weaves them into a unified formulation and plan. When clinicians, patients, and families share this integrated perspective, they are better positioned to make collaborative choices, sustain effort over time, and adapt strategies as life circumstances change. This integrated, flexible, and person‑centered approach offers the best prospect for improving both symptom burden and long‑term functional prognosis in individuals living with FND and its common affective comorbidities.
